Holen Sie sich die Stockscreener-App
23.78
3.65%
-0.90
Vorhandelsmarkt:
24.30
0.52
+2.19%
Schlusskurs vom Vortag:
$24.68
Offen:
$24.4
24-Stunden-Volumen:
2.11M
Relative Volume:
1.25
Marktkapitalisierung:
$4.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-9.0763
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+10.97%
1M Leistung:
+40.71%
6M Leistung:
+50.51%
1J Leistung:
-19.09%
1-Tages-Spanne:
$23.71
$25.17
1-Wochen-Bereich:
$21.05
$26.17
52-Wochen-Spanne:
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
23.78 | 4.30B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Will Immunovant Inc. stock outperform value stocksEarnings Risk Report & Verified Swing Trading Watchlists - newser.com
Sentiment analysis tools applied to Immunovant Inc.Portfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Is Immunovant Inc. stock affected by interest rate hikesQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Is Immunovant Inc. meeting your algorithmic filter criteriaQuarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Can swing trading help recover from Immunovant Inc. lossesJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Why Immunovant Inc. stock is popular among millennialsWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Will Immunovant Inc. stock go up soonJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
How analysts rate Immunovant Inc. stock todayJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Why analysts upgrade Immunovant Inc. stockWeekly Trade Review & Safe Entry Momentum Stock Tips - newser.com
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance
How to use Fibonacci retracement on Immunovant Inc.Portfolio Return Summary & Daily Profit Focused Screening - newser.com
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Analyzing net buyer seller activity in Immunovant Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Key resistance and support levels for Immunovant Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
Is Immunovant Inc. stock oversold or undervaluedWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Immunovant (NASDAQ:IMVT) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha
Published on: 2025-10-31 03:05:59 - newser.com
How institutional ownership impacts Immunovant Inc. stockWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Immunovant gains amid takeover speculation (IMVT:NASDAQ) - Seeking Alpha
IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Immunovant (NASDAQ:IMVT) Shares Up 7.8%What's Next? - MarketBeat
What sentiment indicators say about Immunovant Inc. stockBull Run & Breakout Confirmation Alerts - fcp.pa.gov.br
Graves ophthalmopathy treatment market is expected to reach US$ - openPR.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Oct 22 '25 |
Sale |
19.03 |
2,520 |
47,956 |
200,814 |
| Geffner Michael | Chief Medical Officer |
Oct 08 '25 |
Sale |
16.30 |
1,272 |
20,734 |
220,553 |
| Stout Jay S | Chief Technology Officer |
Oct 08 '25 |
Sale |
16.30 |
1,585 |
25,836 |
203,334 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '25 |
Sale |
18.15 |
2,805 |
50,911 |
204,919 |
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):